Assay methods for prekallikrein and kininogens and their applications.
Prekallikrein activity in plasma was assayed using a synthetic peptidyl fluorogenic substrate (carbobenzoxy-L-phenylalanyl-L-arginine 4-methylcoumarinyl-7-amide), after activation of prekallikrein by acetone and kaolin. For total kininogen assay, the pretreatment of plasma at pH 2.0 was the best to eliminate bradykinin potentiators and kininase activity, before addition of trypsin to convert kininogen to bradykinin. Assay method of high molecular weight (HMW) kininogen was established by conversion of HMW-kininogen to bradykinin through activation of Hageman factor by glass powder and that of low molecular weight (LMW) kininogen was also by treatment of HMW-kininogen-depleted plasma in the same way as that for total kininogen. The marked reduction of prekallikrein and HMW-kininogen, not of LMW-kininogen, was found in pleural fluid of rat carrageenin pleurisy, and in plasma after i.v. injection of bromelain in rats. Members of the pedigree of hereditary angioneurotic edema patients also show low levels of prekallikrein and kininogens in plasma.
D000818:Animals; D001681:Biological Assay; D001920:Bradykinin / Q000032:analysis; D001963:Bromelains / Q000494:pharmacology; D005260:Female; D006801:Humans; D007610:Kallikreins / Q000032:analysis*; D007704:Kininogens / Q000032:analysis / Q000097:blood*; D008297:Male; D009842:Oligopeptides; D010996:Pleural Effusion / Q000032:analysis; D010998:Pleurisy / Q000378:metabolism; D011288:Prekallikrein / Q000032:analysis*; D051381:Rats; D013050:Spectrometry, Fluorescence / Q000379:methods; D013379:Substrate Specificity
D007704:Kininogens; D009842:Oligopeptides; D001963:Bromelains; D011288:Prekallikrein; D007610:Kallikreins; D001920:Bradykinin